Page last updated: 2024-08-25

rosiglitazone and Hepatic Encephalopathy

rosiglitazone has been researched along with Hepatic Encephalopathy in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ding, S; Wang, X; Wen, F; Xu, Z; Yang, J; Zhuge, Q; Zhuge, W1

Other Studies

1 other study(ies) available for rosiglitazone and Hepatic Encephalopathy

ArticleYear
Insulin Resistance Disrupts the Interaction Between AKT and the NMDA Receptor and the Inactivation of the CaMKIV/CREB Pathway in Minimal Hepatic Encephalopathy.
    Toxicological sciences : an official journal of the Society of Toxicology, 2017, 10-01, Volume: 159, Issue:2

    Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Hepatic Encephalopathy; Hippocampus; Hypoglycemic Agents; Insulin Resistance; Maze Learning; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Receptors, N-Methyl-D-Aspartate; Rosiglitazone; Thiazolidinediones

2017